A myo-inositol-related defect in nerve sodium-potassium ATP-
Introduction
Derangements in peripheral nerve metabolism resulting from insulin deficiency and/or hyperglycemia are associated with rapidly reversible abnormalities in nerve function in diabetic animals, and are thought to contribute to progressively less reversible structurally based functional defects in animal and possibly human diabetic neuropathy (1) (2) (3) . A reduction in neural free myo-inositol (MI)' content that accompanies both acute spontaneous and experimentally induced diabetes in rodents appears to underlie a cascade of metabolic and functional defects in nerve, including reduced sodium-potassium ATPase activity and impulse conduction velocity (2, 3) . In the acutely diabetic rat, these abnormalities are completely prevented or reversed by MI supplementation or aldose reductase inhibitors, both of which correct the fall in nerve MI level. Thus, increased polyol (sorbitol) pathway activity appears to contribute to MI depletion and its consequences in diabetic nerve (2) . The MI-related decrease in sodium-potassium ATPase activity has been proposed as the basis for the early and reversible slowing of nerve conduction velocity and paranodal axonal swelling that are also reversed by aldose reductase inhibitors or MI supplementation in spontaneously diabetic BB rats (3) . In vitro exposure to protein kinase C activating phorbol esters or functionally related phosphoinositide-derived diacylglycerols acutely normalizes the MI-related defect in ouabain-sensitive ATPase activity in plasma membranes from diabetic rat sciatic nerve (4) , as well as the diminished ouabain-sensitive respiration (5) and ATPase activity (6) in nerve preparations from alloxan diabetic rabbits, thereby suggesting that protein kinase C is a possible link between MI depletion and its associated sodium-potassium ATPase defect (2) .
The relevance of these metabolic defects to the functional and structural abnormalities underlying human diabetic peripheral neuropathy (and perhaps other chronic complications of diabetes [7, 81) remains controversial. Aldose reductase inhibitors improve nerve conduction in nonneuropathic diabetic patients (9) and ameliorate the sorbitol accumulation (10, I 1) and structural fiber abnormalities (10) in the peripheral nerves of neuropathic diabetic subjects. MI administration also appears to marginally improve nerve conduction in highly selected diabetic neuropathic patients (12) (13) (14) (15) , but not in more heterogeneous populations of diabetic subjects (16, 17) . (The clinical efficacy of aldose reductase inhibitors or MI supplementation await large scale, long-term, randomized, controlled clinical trials with these drugs [10, 16, 17] ). The conflicting and fragmentary reports of measurements of whole nerve MI content in diabetic humans (11, (18) (19) (20) (21) and the reported lack of an effect thereon of aldose reductase inhibitor therapy (1 1, 21) has recently been used to argue that altered MI metabolism is irrelevant to the pathogenesis of diabetic neuropathy (1 1, 22, 23) . This view has been disputed (24, 25) partly on the basis of the fact that MI metabolism is now thought to be highly compartmentalized, and that depletion of a putative small metabolically labile MI pool by glucose during in vitro incubation of aortic intima-media preparations impairs tissue function (including sodium-potassium ATPase activity) in the absence of detectable changes in tissue MI content (26) . One may therefore speculate that pathogenetically significant depletion or repletion in nerve MI could occur in diabetes without detectable alterations in tissue MI content. This communication reports that MI treatment corrects a sorbitol-related defect in amino acid transport in peripheral nerve without correcting the diminished nerve MI content, suggesting that nerve MI content may be an insensitive indicator of polyol pathway-induced defects in MI metabolism.
Methods
Experimental animal model. Male, white New Zealand rabbits weighing 1.5-2.0 kg were fed Wayne Rabbit Ration (Continental Grain Co., Chicago, IL) and fasted overnight before the study or the induction of alloxan diabetes as described previously (27) . Alloxan monohydrate, 90 mg/kg i.v. (Sigma Chemical Co, St. Louis, MO) in 0.73% sodium chloride solution was administered by rapid injection to induce experimental diabetes. Nonfasting plasma glucose concentrations were measured 48 h later, and rabbits with values < 300 mg/dl were excluded. 2 wk thereafter, surviving animals were fasted overnight, and only rabbits with plasma glucose concentrations 2 300 mg/dl were studied. Nondiabetic saline-injected control animals were maintained for 14 d under similar environmental conditions (27) . Sorbinil (Pfizer Central Research, Groton, CT) was suspended in water and administered by gavage daily at a dose of 15 mg/kg beginning 48 h after alloxan administration. MI was similarly administered daily by gavage at a dose of 100 mg/kg.
In vitro peripheral nerve preparations. Endoneurial preparations were derived from the tibial division of the sciatic nerve as previously described in detail (28) . After an overnight fast, diabetic and nondiabetic rabbits were sedated with diazepam, 2 mg/kg i.m. After induction of anesthesia (sodium pentabarbital 24-36 mg/kg i.v.), a defined segment of each sciatic nerve was surgically exposed, ligated, removed with preservation of hemostasis, and transferred to a 125-ml erlenmeyer flask containing 70 mg of collagenase (Type I; Sigma Chemical Co.) dissolved in 10 ml of 4 Standard incubation medium for the endoneurial preparation was 4.5% dialyzed defatted BSA and 5 mM glucose in KRB, pH 7.4, equilibrated with 5% C02/95% 02 as previously described (28) . The endoneurial preparation was routinely equilibrated for 10 min in 3 ml of standard medium in a Dubnoff metabolic shaker set at 88 cycles/min and 37°C. The equilibrated endoneurial preparation was transferred to a new flask containing standard medium for incubation studies lasting as long as 2 h. Phorbol myristate acetate (PMA) was prepared in dimethylsulfoxide (DMSO) (300 ug/ml) and 10 ul added to the incubation flasks for a final PMA concentration of 2 nmol/ml for 1 h (controls received 10 ul of DMSO alone). Other modifications in the incubation conditions for specific studies are described in the relevant portions of the text and figures.
2-Aminoisobutyric acid (AIB) uptake measurements. The preincubated endoneurial preparation was transferred to a new flask containing standard medium with 0.5 ACi/ml of 1-["'Clmannitol 45 mCi/ mmol, and 1 MCi/ml [3H]AIB 20 Ci/mmol (New England Nuclear, Boston, MA) to which unlabeled AIB or MeAIB was added to produce the specified concentrations. To assess the effects of sodium ion in the extracellular fluid on AIB uptake, sodium was replaced by equimolar concentrations of choline during the last 15 min of preincubation and during the exposure to isotopically labeled compounds. Sodium-dependent AIB uptake was defined as the difference in the intracellular uptake in the presence or absence of sodium under each experimental condition.
After brief, timed exposure to isotopically labeled medium the endoneurial preparation was rapidly rinsed in AIB-free standard medium, and frozen in liquid nitrogen. The frozen endoneurial preparation was rapidly weighed on a microbalance, powdered in liquid nitrogen, and homogenized in 6% perchloric acid. Incubation medium was quantitatively transferred to a volumetric flask and diluted to a 5-ml volume with water. Aliquots of diluted medium were deproteinized with equal volumes of 12% perchloric acid. After centrifugation at 2,500 g for 15 (29) . The determinations of MI were performed on trimethylsilyl derivatives of Iyophilized filtrates containing alphao-methyl mannopyranoside as an internal standard in a Varian 3700 gas-liquid chromatograph (Varian Associates, Inc., Palo Alto, CA) on a 6 ft X 4 mm 3% SE-30 Gaschrom Q glass column at 185°C with a nitrogen carrier-gas flow rate of 40 ml/min using a flame ionization detector maintained at 250°C. Standard curves were determined daily, and the recovery of added MI to nerve or plasma samples consistently exceeded 95%. Plasma and sciatic nerve amino acids were quantitated using a Beckman Amino Acid Analyzer (model 6300; Beckman Instruments, Palo Alto, CA) equipped with a fluorometric detector. Plasma samples were precipitated using sulfosalicylic acid (50 mg/ml plasma) and centrifuged. 500 pl of each resulting supernatant were added to 1.0 ml of 0.1 % trifluoroacetic acid containing 30% methanol and filtered through a Waters Sep-Pak (Waters Division, Millipore Corp., Milford, MA) as previously described (30) , and 50 gl of the filtrate injected directly onto the amino acid analyzer. Nerve samples were homogenized in 10 vol of 6% trichloracetic acid, centrifuged, and the supernatants extracted three times with equal volumes of diethylether. The final aqueous phases were lyophilized, reconstituted in 1 ml of 0.1% trifluoroacetic acid/methanol (80:20 vol/vol), filtered through Waters Sep-Paks (30), lyophilized, reconstituted in 125 ,ul of starting buffer for the amino acid analyzer, and small aliquots or dilutions injected. Computations were performed using the external standard method.
Statistical methods. Data were calculated as mean±SEM. Significance of difference between groups was analyzed by Student's twotailed t test. In instances where comparisons were made among multiple groups, a more conservative test for significance would be to compare each P value with 0.050 divided by the number ofgroups, which is the Bonferroni adjustment to the P value. The differences between paired samples were analyzed by the t test for paired comparisons. Kinetic analysis of AIB uptake was performed by the Eadie-Hofstee and Lineweaver-Burk transformations of the Michaelis-Menten equation. Linear regression analysis was performed by the method of least squares.
Results
AIB uptake in endoneurial preparations from nondiabetic rabbits Linearity with respect to time (Fig. 1) . The intracellular uptake of 2.5 mM AIB was linear with time for 15 min after preincubation in AIB-free medium for 1 h (Fig. 1 ) or 2 h (data not shown). When medium sodium was replaced with equimolar concentrations of choline, AIB uptake remained linear with time for 15 min, but uptake was reduced by about half. Paired 10-min incubations in medium containing sodium or choline were routinely employed to estimate the initial rate ofcomposite (sodium-dependent + sodium-independent) and sodiumdependent AIB uptake.
Effect of medium AIB concentration (Fig. 2) . Composite intracellular AIB uptake was assessed during 10-min incubations in the presence of sodium ion at AIB concentrations between 0.5 and 12.5 mM. Composite AIB uptake increased rapidly with AIB concentration below 2.5 mM, after which AIB uptake continued to increase but at a slower rate (Fig. 2 , solid line). This pattern was consistent with the presence oftwo transport components, a higher affinity one that became fully saturated and a lower affinity one, which demonstrated little or no saturation over the AIB concentration range tested.
Effect ofsodium gradient ( Fig. 2 and 3 , Table I ). To determine which component constituted sodium-dependent cotransport, uptake of 0.5-12.5 mM AIB was studied in the absence of extracellular sodium. The initial rate of AIB uptake increased linearly with concentration (r = 0.994, y-intercept = 33 nmol/kg per min, slope = 253 nmol/kg per min per mM; Fig. 2 , dotted line), suggesting that sodium-independent uptake did not saturate within the concentration range tested. Sodium-dependent uptake velocity (composite uptake -sodium-independent uptake) increased as a function of AIB concentration, but at a progressively decreasing rate, suggesting a saturable uptake process (Fig. 2, dashed dium-dependent uptake of 2.5 mM AIB was measured after a 10-min preincubation with and in the presence of 2 mM ouabain. Sodium-dependent 2.5 mM AIB uptake was virtually completely inhibited by ouabain suggesting that AIB uptake is sodium gradient dependent (Table I) , while 2.5 mM sodiumindependent uptake was unaffected by ouabain: 691±164 nmol/kg per min, n = 6, with and 724±120 nmol/kg per min, n = 7, without 2 mM ouabain, P = NS.)
Although AIB is transported by the sodium-cotransport system specific for amino acids with short, polar or linear side chains ("system A"), AIB is also transported by other carriers as well in some cells (31). Therefore, the ability of excess MeAIB, a system A-specific substrate, to inhibit sodium-gradient dependent AIB uptake was explored. The uptake of 1 mM (3H]AIB in the presence of 10 mM MeAIB was marginally (but statistically significantly) affected by the presence of sodium ion in the incubation medium (239±13 nmol/kg per min without sodium vs. 323±32 nmol/kg per min with sodium, mean delta ofpaired samples +84±29 nmol/kg per min, n = 6, P < 0.05); this implies that at this AIB concentration, 30% of non-system A AIB uptake was sodium dependent. Sodium-dependent uptake of 1 mM AIB in the absence of MeAIB was 636±141 nmol/kg per min (n = 4) (Fig. 2) so that residual (non-system A) sodium-dependent AIB uptake comprised only 13% of total sodium-dependent AIB uptake. Thus at least 87% of sodium-dependent 1 mM AIB uptake would appear to occur via system A (31).
When sodium-dependent AIB uptake and medium AIB concentration were plotted as their double reciprocals (Fig. 3  A) or when uptake was plotted as a function of the ratio of uptake to medium AIB concentration (Eadie-Hofstee transformation, Fig. 3 B) , linear relationships were generated (r = 0.998 and 0.973, respectively). By the Lineweaver-Burk transformation of the Michaelis-Menten equation, the apparent transport constant (K, = concentration for half-maximal rate of uptake) was 2.44 mM and the apparent maximal transport velocity (Vma.) was Effect of 14 day alloxan diabetes on endoneurial AIB uptake (Table II, Figs. 4 and 5) . In order to assess the effect of experimental diabetes on nerve sodium-dependent amino acid uptake, composite and sodium-independent uptake was measured in endoneurial preparations derived from rabbits with untreated alloxan diabetes of 14 d duration. Untreated alloxan diabetes was associated with significant reductions in body weight and sciatic nerve MI content, elevation in fasting plasma glucose concentration, but no change in fasting plasma MI content (Table II, lines 1 and 2 ). Composite AIB uptake was generally reduced over the concentration tested, while sodium-independent AIB uptake was essentially intact (Fig. 4) . The selective effect of experimental diabetes on the sodiumdependent component of AIB uptake was confirmed in paired experiments with a medium AIB concentration of 2.5 mM (Fig. 5) Effects ofelevated ambient glucose concentration and insulin on endoneurial sodium-dependent AIB uptake (Table I) . Because experimental diabetes perturbs both plasma insulin and glucose concentrations, the acute effects of both elevated ambient glucose concentration, and physiologic or supraphysiologic concentrations of insulin on endoneurial AIB uptake were tested. Nondiabetic endoneurial preparations were preincubated and incubated in the presence of 20 mM glucose, or 100 or 1,000 uU/ml insulin (crystalline porcine; Eli Lilly Composite (solid line, filled circles) and sodium-dependent (triangles) AIB uptake was measured, and sodium-independent AIB uptake (not shown) computed as described in the previous figure. Apparent sodium-dependent uptake, which became negative at high AIB concentrations, was not graphed for clarity. The regression line for sodium-independent uptake in non-diabetic endoneurial preparations from Fig. 2 nerve MI but did not affect body weight, plasma glucose, or plasma MI in alloxan diabetic rabbits (Table II, line 3) . Sodium-dependent AIB uptake in endoneurial preparations from alloxan diabetic animals treated with sorbinil was no longer significantly different from that of nondiabetic controls (Fig. 5) . MI supplementation did not alter body weight or plasma glucose in alloxan diabetic rabbits and raised neither nerve MI, nor plasma MI after an overnight fast (Table II, line  4) . However, MI supplementation similarly and significantly raised composite and sodium-dependent AIB uptake in the presence of 2.5 mM AIB (Fig. 5) . To better define the action on AIB uptake of MI supplementation that altered neither fasting plasma nor nerve MI, plasma MI was monitored frequently after administration of 100 mg/kg MI by gavage to nondiabetic rabbits (Fig. 6 ). Peak plasma MI concentration 2 h after gavage was not statistically significantly lower than that which normalized sciatic nerve MI level and sodium-potassium ATPase in streptozotocin-diabetic rats fed 1% MI diets (2), but plasma MI returned to baseline in the rabbit within 24 h after gavage with MI (Fig. 6 ). Thus gavage with 100 mg/kg MI in the rabbit reproduced the plasma concentrations resulting from 1% MI diets in the rat, but only transiently. Daily gavage with a 10-fold higher dose of MI did correct sciatic nerve MI content (5.73±0.64 mmol/kg, n = 6, P = ns vs. non-diabetic [Table II ,
Effect of alloxan diabetes on plasma and sciatic nerve amino acid levels (Table III) . Experimental diabetes raised the plasma concentration of the branched-chain amino acids (BCAA's: leucine, isoleucine and valine) and aspartate, and lowered the concentration of alanine, while producing opposite trends in the concentrations ofthese amino acids in sciatic nerve (Table III) . Therefore, the inhibition of sodium-dependent AIB uptake by diabetes could not be readily attributed to a "trans effect" resulting from increased intracellular levels of amino acids with short, polar or linear side chains (31).
Effect ofin vitro exposure to PMA on diabetic endoneurial AIB uptake. To determine if normalization of sodium-potassium ATPase activity in diabetic nerve rapidly corrected sodium-gradient dependent AIB uptake, endoneurial AIB up- (27) reduces nerve MI content and sodium-potassium ATPase activity (6) , and markedly depresses endoneurial sodium-gradient dependent (but not sodium-independent) AIB uptake over a concentration range extending fivefold above and below the apparent K,. Decreased AIB uptake cannot be explained on the basis of a "trans effect" due to increased intraneural concentrations of system A-transported amino acids, or by alterations in AIB efflux since sodium-dependent AIB uptake was essentially unidirectional during the brief experimental periods employed in these studies. Neither hyperglycemic concentrations ofglucose nor physiologic or supraphysiologic concentrations of insulin acutely affect AIB uptake in vitro in nondiabetic endoneurial preparations at the K,. Administration of an aldose reductase inhibitor that normalizes nerve MI levels corrects the reduction in sodium-gradient dependent AIB uptake after 2 wk of experimental diabetes. MI supplementation (that in the diabetic rat does not alter nerve polyol pathway intermediates [29] ) also corrects sodium-gradient dependent AIB uptake, implicating MI depletion in this transport defect in diabetic peripheral nerve. However, the MI supplementation that reproduced the effect of sorbinil on sodium-dependent AIB uptake did not significantly raise the overall tissue MI content of diabetic rabbit sciatic nerve. As discussed below, this apparent paradox is consistent with the concept of Winegrad and coworkers who postulate that depletion or repletion of a specific small metabolically labile pool of tissue MI which is poorly reflected by changes in overall tissue MI content may be particularly relevant to abnormalities in membrane transport in diabetic tissues (8, 26) . This concept was recently extended to renal tubular transport by the suggestion that impaired renal tubular sodium-dependent ascorbate transport in the streptozotocin-diabetic rat is corrected by dietary MI supplementation without any concomitant change in renal cortical or medullary MI content (34) . Diabetes raises plasma BCAA levels in the rat (35) , man (36) , and the rabbit. The parallel increases in plasma and brain BCAA in the diabetic rat (35) contrast with the paradoxical decrease in diabetic rabbit peripheral nerve BCAA level, though this difference did not attain statistical significance. While species effects cannot be excluded, these divergent responses in brain and peripheral nerve BCAA's to the raised plasma BCAA levels in diabetes more likely reflects a fundamental differences in brain and nerve amino acid transport: system A transport occurs in peripheral nerve but not at the blood-brain barrier (37) where sodium-independent bidirectional system L would facilitate equilibration of brain and plasma BCAA levels, while the uptake of other large neutral amino acids would be reduced in diabetes due to competitive inhibition by BCAA's (37) . In peripheral nerve, active system-A uptake would greatly exceed influx via the bidirectional system L, which would promote efflux of amino acids transported in common and competitively by both systems (38) . (The failure to detect a fall in system A amino acid content despite diminished AIB uptake in diabetic nerve may reflect the large tissue pool of system A amino acids [38] .) System L amino acids (BCAA's, tyrosine and phenylalanine) tended to be lower in diabetic nerve, though not statistically significantly so, consistent with a reduction in system A amino acid transport and the much smaller tissue pool size of system L amino acids. Thus the observed effects of diabetes on amino acid content in diabetic rabbit nerve are not inconsistent with a significant reduction in vivo in sodium-dependent system A amino acid transport in diabetic nerve.
MI regulates intracellular metabolism primarily through its incorporation into inositol-containing membrane phospholipids that serve as precursors for phospholipase-C-generated inositol-phosphate and diacylglycerol second messengers (39) . The known relationship(s) between phosphoinositide signaling and membrane transport are widespread and complex, involving highly regulated inositol-1,4,5-trisphosphate-and inositol-1,4,5-tetrakisphosphate-mediated intracellular (40, 41) and transplasmalemmal (40) calcium fluxes, and diacyl-glycerol-mediated stimulation of phospholipid-and-calcium-dependent protein kinase C (39) . Protein kinase C agonists affect growth and differentiation in some cells, and have multiple effects on membrane transport such as the induction of the glucose transporter gene (42) . In LLC-PK' cells, PKC-mediated activation of system A sodium-dependent amino acid transport is demonstrable primarily in confluent cells with constitutively low amino acid uptake but not in dividing cells with constitutively high amino acid transport (43) . The sorbinil-and MI-sensitive defect in amino acid transport in diabetic peripheral nerve may be a direct consequence of the estimated fourfold rise in intraaxonal sodium (ifthe AIB transport defect resides in the axonal compartment), or a similar reduction in the transmembrane electrochemical sodium-gradient in the Schwann cell, both of which may reflect impaired sodium-potassium ATPase activity (3). Alternatively, MI depletion in diabetic nerve may independently reduce sodiumpotassium ATPase activity and sodium-dependent AIB uptake, the latter possibly via an indirect mechanism analogous to that described in quiescent LLC-PK' cells (43) . The fact that PMA, a protein kinase C agonist that rapidly corrects the MIrelated reduction in sodium-potassium ATPase in diabetic rabbit and rat nerve (4-6), does not acutely improve sodiumgradient dependent AIB uptake in vitro in endoneurial preparations from diabetic rabbits implies that these two processes are independent, or that the reestablishment of the normal electrochemical sodium gradient is delayed once sodium-potassium ATPase activity is restored. A third possibility, that impaired sodium-gradient dependent AIB uptake in diabetic peripheral nerve represents a consequence of MI depletion at some distant site (perhaps the anterior horn or dorsal root ganglia neuronal cell body) that is fully corrected by MI-supplementation, cannot be rigorously excluded. In any case, both sodium-dependent AIB uptake and sodium-potassium ATPase activity appear to be reduced in diabetic nerve as a result of underlying MI depletion. These two defects may be linked serially or in parallel, and may involve one or more metabolic pools of MI, and/or distinct but phosphoinositide-related processes (39) . All of these possibilities imply that metabolism ofa specific MI pool or pools rather than the total tissue MI content mediate some of the effects of MI depletion and repletion on nerve metabolism such as the defect in system A amino transport, as has been suggested by Winegrad and his colleagues (8, 26) .
Although rapidly reversible slowing of nerve conduction in human (9, 44) and animal (45) diabetes theoretically may be attributable in part to acute alterations in nerve MI metabolism, most but not all slowing of nerve conduction in established diabetes and diabetic neuropathy is thought to reflect nerve fiber loss, atrophy, and/or demyelination (46) . Reduced leucine incorporation into myelin in diabetic rodent nerve has been postulated to be a contributing factor to peripheral nerve hypomyelination in diabetes (47, 48) . This defect may reflect impaired amino acid uptake by diabetic peripheral nerve in vitro (while this defect appeared to be partially insulin sensitive, pharmacological concentrations ofinsulin far in excess of those employed in the present report were required (46) ). Reduced amino acid uptake by dorsal root ganglia from the streptozotocin diabetic rat is associated with diminished sodium-potassium ATPase activity, and has been invoked in the accompanying axonal "dwindling" or "atrophy" (49, 50) . Hence chronically reduced MI-and sorbinil-responsive sodium-dependent amino acid uptake in axons and/or Schwann cells may be important links between acute metabolic derange-ments and chronic structural defects in diabetic nerve, thereby providing a plausible mechanism by which longstanding alterations in nerve MI metabolism induced by hyperglycemia might contribute to the pathogenesis of the structural hallmarks of chronic diabetic neuropathy.
In summary, important polyol-pathway related abnormalities in MI metabolism in diabetic peripheral nerve, such as that responsible for impaired sodium-amino acid cotransport, may be corrected by MI supplementation that fails to detectably alter the concurrent decrease in whole-nerve MI content. This most likely reflects the fact that the metabolically active, physiologically important MI pools in the peripheral nervous system may represent only a small fraction of, and/or be poorly reflected by, the composite tissue MI content of peripheral nerve. Therefore, the presence or absence of alterations in whole tissue MI content in response to diabetes or metabolic intervention are poor indicators of the presence or absence of physiologically and perhaps pathogenetically important abnormalities in MI or phosphoinositide metabolism.
